SurVaxM

DRUG3 trials

Sponsors

David Peereboom, Roswell Park Cancer Institute, MimiVax, LLC

Conditions

GlioblastomaNewly Diagnosed GlioblastomaRecurrent Glioblastoma

Phase 2

Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence

CompletedNCT04013672

David PeereboomRecurrent Glioblastoma

Start: 2020-03-19End: 2022-02-16Updated: 2024-08-28

SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)

Active, not recruitingNCT05163080

MimiVax, LLCNewly Diagnosed Glioblastoma

Start: 2021-11-18End: 2024-08-18Target: 247Updated: 2024-02-26

Unknown Phase

SurVaxM Expanded Access Protocol

Roswell Park Cancer InstituteGlioblastoma

Updated: 2025-09-16

Related Papers

RTID-04. A MULTICENTER, RANDOMIZED, CONTROLLED PHASE 2B TRIAL OF SURVIVIN VACCINE SURVAXM PLUS ADJUVANT TEMOZOLOMIDE FOR NEWLY-DIAGNOSED GLIOBLASTOMA (SURVIVE)

Neuro-Oncology2024-11-01

A multicenter, randomized controlled phase 2b trial of survivin vaccine SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma (SURVIVE).

Journal of Clinical Oncology2024-06-014 citations

P07.09.B A RANDOMIZED PHASE 2B STUDY OF SURVIVIN VACCINE SURVAXM PLUS ADJUVANT TEMOZOLOMIDE FOR NEWLY-DIAGNOSED GLIOBLASTOMA (SURVIVE)

Neuro-Oncology2023-09-012 citations

Phase II study of pembrolizumab plus SurVaxM for glioblastoma at first recurrence.

Journal of Clinical Oncology2020-05-2012 citations